Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1996 Nov;196(11):734-6.

[Antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus]

[Article in Spanish]
F Formiga  1 , I Moga, R Canet, M Pac, F Mitjavila, R Pujol
Affiliations
  • PMID: 9132835

[Antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus]

[Article in Spanish]
F Formiga et al. Rev Clin Esp. 1996 Nov.

Abstract

Objective: To verify the possible relationship between the presence of antiphospholipid antibodies (APLA) and the presence of epileptic seizures in patients with systemic lupus erythematosus (SLE).

Methods: A total of 168 patients with SLE were studied. Fifteen patients had antecedents of epilepsy which were non attributable to a cause other than SLE. Epilepsy was diagnosed on clinical and electroencephalographic grounds. Antibodies to cardiolipin (CLa) and lupus anticoagulant (LA) were measured.

Results: Epileptic seizures were generalized in 13 and partial in two patients. The lupus anticoagulant was positive in 40% of patients with epilepsy compared to 32% in the control group; CLa IgG in 53.5% compared to 65.6%, and CLa IgM in 40% compared to 35.2%. Differences were never statistically significant. Neither when patients with moderate/high CLa levels were studied. Seven patients (40%) had some of the classical manifestations of antiphospholipid syndrome.

Conclusions: No association was found between positive APLA and epilepsy in patients with SLE.

PubMed Disclaimer

Publication types

Substances